ARCHIVES

Risk-Benefit Analysis Advised Prior To Hormone Therapy

This article is from The Cancer Letter archive.

Vol. 33 No. 8 | August 27, 2010

Download PDF Visit The Full Archive

Related Articles

Groups Have No Budgets As NCTN Begins Work March 1

February 28, 2014

After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant

July 11, 2014

Funding opportunities listed.

March 26, 2004

Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%

June 28, 2013

Obituary: Rajka Medenica, controversial Physician

December 5, 1997

NCI Advisors Approve New Grant Programs Worth $100 Million

March 27, 2009